HCW Biologics rises as US FDA approves trial for hair loss treatment

Hcw Biologics

03/02/2025 14:58

** Shares of drug developer HCW Biologics  HCWB.O  rise 252%
to 97 cents
    ** HCWB says it received U.S. FDA's clearance to start
clinical trial for treatment of moderate-to-severe alopecia
areata, which is an autoimmune disease that causes sudden hair
loss
    ** HCWB says drug HCW9302 is protein therapy that helps
reduce inflammation and promote hair growth
    ** Co says if trial is successful, HCW9302 may also be used
to treat other diseases, including skin conditions, arthritis,
and diabetes
    ** More than 154 mln shares traded, 578x their 25-day moving
average
    ** HCWB shares fell 62.5% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))